Clinical Trials Logo

Head and Neck Cancer Stage IV clinical trials

View clinical trials related to Head and Neck Cancer Stage IV.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05526924 Recruiting - Clinical trials for Head and Neck Cancer

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Start date: March 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after treatment. Participation in the study should last for about 15 months while participants receive tislelizumab and chemoradiotherapy with pamiparib. Afterwards, they will return to the clinic for follow up every 4 months for 2 years, every 6 month for the next 2 years, and then once a year for the rest of their life.

NCT ID: NCT03993353 Recruiting - Cancer Clinical Trials

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Start date: April 7, 2020
Phase: Phase 2
Study type: Interventional

This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.

NCT ID: NCT03795610 Recruiting - Clinical trials for Head and Neck Cancer

Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Start date: March 6, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate how effective the study drug IPI-549 is against types of cancers. IPI-549 is considered experimental because it is not approved by the US Food and Drug Administration (FDA) for the treatment of cancer. Patients will be treated with 2 weeks of IPI-549, a specific PI3Kγ inhibitor. Tumor tissue for research purposes through core biopsies will be obtained prior to initiation of IPI-549 and at surgery.